Ustekinumab 90 mg ( DrugBank: Ustekinumab )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	1
93	原発性胆汁性胆管炎	1
96	クローン病	3

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03517722 (ClinicalTrials.gov)	April 16, 2018	13/4/2018	A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in ...	Lupus Erythematosus, Systemic	Drug: Placebo;Drug: Ustekinumab (approximately 6 mg/kg);Drug: Ustekinumab 90 mg	Janssen Research & Development, LLC	NULL	Terminated	16 Years	75 Years	All	516	Phase 3	United States;Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lith ...

First Previous1Next Last

93. 原発性胆汁性胆管炎

臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01389973 (ClinicalTrials.gov)	September 2011	7/7/2011	A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who H ...	A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluati ...	Primary Biliary Cirrhosis	Drug: ustekinumab 90 mg;Drug: ustekinumab 45 mg;Drug: ustekinumab 180 mg;Drug: Placebo	Janssen Research & Development, LLC	NULL	Completed	18 Years	99 Years	All	20	Phase 2	United States;Canada

First Previous1Next Last

96. クローン病

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03782376 (ClinicalTrials.gov)	December 20, 2018	11/12/2018	A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Mod ...	A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intra ...	Crohn Disease	Drug: Ustekinumab approximately 6 mg/kg (IV);Drug: Placebo (SC);Drug: Placebo (IV);Drug: Ustekinumab ...	Janssen-Cilag Ltd.	NULL	Completed	18 Years	N/A	All	215	Phase 3	United States;Austria;Czechia;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation ...
2	NCT01369355 (ClinicalTrials.gov)	September 13, 2011	7/6/2011	A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Mode ...	A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evalua ...	Crohn's Disease;Colitis;IBD;Inflammatory Bowel Disease	Drug: Placebo SC;Drug: Placebo IV;Drug: Ustekinumab 90 mgSC q8w;Drug: Ustekinumab 130 mg IV;Drug: Us ...	Janssen Research & Development, LLC	NULL	Completed	18 Years	99 Years	All	1282	Phase 3	United States;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;France;German ...
3	NCT00265122 (ClinicalTrials.gov)	April 2004	13/12/2005	A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease	A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Su ...	Crohn Disease	Drug: Ustekinumab 90 mg;Drug: Ustekinumab 4.5 mg/kg;Drug: Placebo SC;Drug: Placebo IV	Centocor, Inc.	NULL	Completed	18 Years	N/A	All	131	Phase 2	United States;Belgium;Canada

First Previous1Next Last

先頭へ